Information Provided By: 
Fly News Breaks for January 11, 2017
SRPT
Jan 11, 2017 | 09:03 EDT
After Sarepta reported that it had obtained revenue of more than $5M from its Exondys 51 drug, JMP Securities analyst Liisa Bayko says that the drug is off to a "solid start." The analyst expects the drug to be launched in the EU in 2019 and continues to recommend the stock.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
